Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Trodelvy improved PFS by 34% in heavily pre-treated patients

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 11, 2023 4:07pm

130 Views

Post# 35490747

RE:RE:RE:RE:RE:RE:Trodelvy improved PFS by 34% in heavily pre-treated patients

westcoast - you're right in that Gilead didn't request an AA for Trodelvy in HR+/HER- mBC - for reasons we don't know but can speculate on, that perhaps having to do with Trodely's side effect profile and QoL in this indication.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta